The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research. The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Immuno-oncology, also called as cancer immunotherapy is a biologic treatment, which enhances the body’s natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.
Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.
Request for sample copy of this report @https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample
The global immuno-oncology market is driven by the factors such as rising occurrence of different forms of cancer, technological advancements in the field of immune oncology for cancer treatment, and rising awareness concerning the benefits of ablation procedures over conventional treatment procedures. Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally. Additionally, the developments in oncology treatments, leading to the increased development of pioneering products are also advancing towards significant growth of the global Immune Oncology market.
The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.
On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of cancer type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2019 i.e. 15.31% among the listed tumor types in the report.
On the basis of geography, North America was the largest regional market in 2019. High levels of spending on cancer treatments, also U.S. being one of the major country y with a huge population of cancer affected people on a global scale, the country being the host to the development of this technology, higher frequency of innovations of immuno oncology treatments or processes in the region specially in the U.S. etc., all of these factors have driven significant investment and alongside the demand for IO in the region. These factors have driven the North American market since the inception of this technology and over the forecast period it is expected to increase further.
Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.
Polaris Market research has segmented the Immuno-oncology market report on the basis of Treatment Approaches, novel targets, tumor types, and by region
Immuno-Oncology Treatment Approach Outlook (Revenue, USD Million, 2015 – 2025)
- Monoclonal Antibodies
- Therapeutic Vaccines
- Checkpoint Inhibitors
- Cytokines
Immuno-Oncology Novel Target Outlook (Revenue, USD Million, 2015 – 2025)
- IDO1i
- LAG-3 CPI
- Oncolytic virus
- STING agonist
- TLR agonist
- HDACi
- TIL
- VEGFi
- MEKi
- TIGIT
- CPI
- GITR agonist
- TGF-b trap
- A2AR antagonist/CD73i
Immuno-Oncology Tumor Type Outlook (Revenue, USD Million, 2015 – 2025)
- Melanoma
- Non-Small Cell Lung Cancer
- Renal Cell Carcinoma
- Head & Neck Cancer
- Bladder Cancer
- Classical Hodgkin’s Lymphoma
- Merkel Cell Carcinoma
- Others
Immuno-Oncology Regional Outlook (Revenue, USD Million, 2015 – 2025)
- North America (U.S., Canada, Mexico)
- Europe (Germany, UK)
- Asia-Pacific (China, Japan, India)
- Latin America (Brazil)
- Middle East and Africa
Request for Discount on This Report @https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world
Contact us
Polaris Market Research
Phone: 1-646-568-9980
Email: [email protected]
The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research.
This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function.Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
The more precise targeting of patients for selected therapies is another important area of focus in oncology.
Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.
Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/immuno-oncology-io-market/request-for-sample Some of the key players operating in global immuno-oncology market are Bristol Myers Squibb, Merck, AstraZeneca, Roche Holding AG, Pfizer Inc., and Incyte Corporation among others.
Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally.
The global immuno-oncology market size is expected to reach USD 38.89 billion by 2025 according to a new study by Polaris Market Research.
The report “Immuno Oncology (I-O) Market Size, Trends, Industry Analysis By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines); By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i); By Tumor Types; By Region: Market Size & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The more precise targeting of patients for selected therapies is another important area of focus in oncology.
Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.
Moreover, rising number of ablation centers, surgical centers, and hospitals are driving the growth of tumor ablation market globally.
The Report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.
Market HighlightsThe North America clinical laboratory test market has been evaluated as rapidly growing market and expected that the market will reach high growth figures.
Other factors such as increasing prevalence of disease, growth of outpatient services, government funds new payment and service delivery model and expansion of hospital outreach services are the adding to the market growth of clinical laboratory market in North America.
Government rules and regulations cheaper services in government owned hospitals and increasing interest rates are some of the factors acting as restraints for the global clinical laboratory test market.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/2249Certainly, both the companies offer a wide range of diagnostic testing services, right from routine CBC testing to prenatal tests, and further to highly sensitive cancer and genetics tests.
LabCorp follows Quest and accounting for second largest market share of the domestic market but is growing at a faster pace than its main rival.
In addition to this, Spectra (U.S.), Renalab Inc. (U.S.), Berkeley Heart Lab (U.S.), and others together contributes more than 60% of the market share of total market.North America clinical laboratory test market Players:The key players are AURORA Diagnostic (USA), Laboratory Corporation of America (US), LifeLabs Medical Laboratories (Canada), and Quest Diagnostics (US).Segmentation:The North America clinical laboratory test market is majorly segmented on the basis of type of laboratory, type of test, and by country.
Based on the type of laboratory, the market is segmented into hospital-based laboratory, central/ independent laboratory, physician office laboratory, and others.
